147 related articles for article (PubMed ID: 37345354)
1. NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol.
Wedekind MF; Reilly KM; Rivero JD; Lockridge R; Allen T; Raygada M; Bernstein D; Thomas BJ; Vivelo C; Levine J; Shonkoev N; Aldape K; Glod J; Sandler AB; Widemann BC
Pediatr Blood Cancer; 2023 Jun; ():e30495. PubMed ID: 37345354
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.
Ahmed S; Wedekind MF; Del Rivero J; Raygada M; Lockridge R; Glod JW; Flowers C; Thomas BJ; Bernstein DB; Kapustina OB; Jain A; Miettinen M; Raffeld M; Xi L; Tyagi M; Kim J; Aldape K; Malayeri AA; Kaplan RN; Allen T; Vivelo CA; Sandler AB; Widemann BC; Reilly KM;
Cancer Res Commun; 2023 Dec; 3(12):2468-2482. PubMed ID: 37966258
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop.
Penas-Prado M; Theeler BJ; Cordeiro B; Dunkel IJ; Hau P; Mahajan A; Robinson GW; Willmarth N; Aboud O; Aldape K; Butman JA; Gajjar A; Kelly W; Rao G; Raygada M; Siegel C; Romo CG; Armstrong TS; Gilbert MR;
Neurooncol Adv; 2020; 2(1):vdaa097. PubMed ID: 33005896
[TBL] [Abstract][Full Text] [Related]
4. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
5. NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings.
Theeler BJ; Dalal Y; Monje M; Shilatifard A; Suvà ML; Aboud O; Camphausen K; Cordova C; Finch E; Heiss JD; Packer RJ; Romo CG; Aldape K; Penas-Prado M; Armstrong T; Gilbert MR
Neurooncol Adv; 2020; 2(1):vdaa007. PubMed ID: 32642676
[TBL] [Abstract][Full Text] [Related]
6. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.
Penas-Prado M; Wu J; Cahill DP; Brat DJ; Costello JF; Kluetz PG; Cairncross JG; van den Bent M; Verhaak RGW; Aboud O; Burger P; Chang SM; Cordova C; Huang RY; Rowe LS; Taphoorn MJB; Gilbert MR; Armstrong TS;
Neurooncol Adv; 2020; 2(1):vdz048. PubMed ID: 33289010
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Impact of biobanks on research outcomes in rare diseases: a systematic review.
Garcia M; Downs J; Russell A; Wang W
Orphanet J Rare Dis; 2018 Nov; 13(1):202. PubMed ID: 30419920
[TBL] [Abstract][Full Text] [Related]
9. The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor.
John L; Smith H; Ilanchezhian M; Lockridge R; Reilly KM; Raygada M; Dombi E; Sandler A; Thomas BJ; Glod J; Miettinen M; Allen T; Sommer J; Levy J; Lozinsky S; Dix D; Bouffet E; MacDonald S; Mukherjee D; Snyderman CH; Rowan NR; Malyapa R; Park DM; Heery C; Gardner PA; Cote GM; Fuller S; Butman JA; Jackson S; Gulley JL; Widemann BC; Wedekind MF
Pediatr Blood Cancer; 2023 Jun; ():e30358. PubMed ID: 37347686
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.
Truitt G; Gittleman H; Leece R; Ostrom QT; Kruchko C; Armstrong TS; Gilbert MR; Barnholtz-Sloan JS
J Neurooncol; 2019 Aug; 144(1):53-63. PubMed ID: 31209773
[TBL] [Abstract][Full Text] [Related]
12. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
13. Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study.
Asare M; Heckler CE; Culakova E; Kamen CS; Kleckner AS; Minasian LM; Wendler DS; Feige M; Weil CJ; Long J; Cole SK; Onitilo AA; Peppone LJ; Morrow GR; Janelsins MC
J Cancer Educ; 2020 Apr; 35(2):292-300. PubMed ID: 30612315
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Cohort Study of Gender Affirmation and HIV-Related Health in Transgender and Gender Diverse Adults: The LEGACY Project Protocol.
Reisner SL; Deutsch MB; Mayer KH; Potter J; Gonzalez A; Keuroghlian AS; Hughto JM; Campbell J; Asquith A; Pardee DJ; Pletta DR; Radix A
JMIR Res Protoc; 2021 Mar; 10(3):e24198. PubMed ID: 33646126
[TBL] [Abstract][Full Text] [Related]
15. Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention Study.
Feldman HH; Belleville S; Nygaard HB; Montero-Odasso M; Durant J; Lupo JL; Revta C; Chan S; Cuesta M; Slack PJ; Winer S; Brewster PWH; Hofer SM; Lim A; Centen A; Jacobs DM; Anderson ND; Walker JD; Speechley MR; Zou GY; Chertkow H
J Prev Alzheimers Dis; 2023; 10(4):875-885. PubMed ID: 37874110
[TBL] [Abstract][Full Text] [Related]
16. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
17. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
Rees S; Williams A
JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
[TBL] [Abstract][Full Text] [Related]
18. The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.
Flores-Toro JA; Jagu S; Armstrong GT; Arons DF; Aune GJ; Chanock SJ; Hawkins DS; Heath A; Helman LJ; Janeway KA; Levine JE; Miller E; Penberthy L; Roberts CWM; Shalley ER; Shern JF; Smith MA; Staudt LM; Volchenboum SL; Zhang J; Zenklusen JC; Lowy DR; Sharpless NE; Guidry Auvil JM; Kerlavage AR; Widemann BC; Reaman GH; Kibbe WA; Doroshow JH;
J Clin Oncol; 2023 Aug; 41(24):4045-4053. PubMed ID: 37267580
[TBL] [Abstract][Full Text] [Related]
19. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
[TBL] [Abstract][Full Text] [Related]
20. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network.
Merkel PA; Manion M; Gopal-Srivastava R; Groft S; Jinnah HA; Robertson D; Krischer JP;
Orphanet J Rare Dis; 2016 May; 11(1):66. PubMed ID: 27194034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
